Journal Home > Volume 8 , Issue 2
Journal of Neurorestoratology 2020, 8(2): 61-82 https://doi.org/10.26599/JNR.2020.9040009
Review Article | Open Access | Issue | Published: 04 August 2020

Clinical neurorestorative cell therapies: Developmental process, current state and future prospective

Show Author's Information Hongyun Huang1,2( ),  Lin Chen3,  Gengsheng Mao1,  Hari Shanker Sharma4
Institute of Neurorestoratology, The Third Medical Centre, Chinese PLA General Hospital, Beijing 100853, China
Beijing Hongtianji Neuroscience Academy, Beijing 100144, China
Department of Neurosurgery, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine Beijing 100007, China
Int. Exp. CNS Injury & Repair, Neurobiology (MRC) & Neuroanatomy (UU), Uppsala University, University Hospital, Anesthesiology & Intensive Care Medicine, Dept. Surgical Sciences, Uppsala, Sweden
Keywords:
olfactory ensheathing cells, cell therapy, mature/functional cells, neurorestoration, stem cell-derived cell therapy product
Cite this article:
Huang H, Chen L, Mao G, et al. Clinical neurorestorative cell therapies: Developmental process, current state and future prospective. Journal of Neurorestoratology, 2020, 8(2): 61-82. https://doi.org/10.26599/JNR.2020.9040009
Download citation
EndNote(RIS)
BibTeX

873

Views

73

Downloads

Citations

22

Crossref

24

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

Clinical cell therapies (CTs) for neurological diseases and cellular damage have been explored for more than 2 decades. According to the United States Food and Drug Administration, there are 2 types of cell categories for therapy, namely stem cell-derived CT products and mature/functionally differentiated cell-derived CT products. However, regardless of the type of CT used, the majority of reports of clinical CTs from either small sample sizes based on single-center phase 1 or 2 unblinded trials or retrospective clinical studies showed effects on neurological improvement and the ability to either partially or temporarily thwart the deteriorating cellular processes of the neurodegenerative diseases. There have been only a few prospective, multicenter, randomized, double- blind placebo-control clinical trials of CTs so far in this developing novel area that have shown negative results, and more clinical trials are needed. This will expand our knowledge in exploring the type of cells that yield promising results and restore damaged neurological structure and functions of the central nervous system based on higher level evidence-based medical data. In this review, we briefly introduce the developmental process, current state, and future prospective for clinical neurorestorative CT.


menu
Abstract
Full text
Outline
About this article

Clinical neurorestorative cell therapies: Developmental process, current state and future prospective

Show Author's information Hongyun Huang1,2( ), Lin Chen3, Gengsheng Mao1, Hari Shanker Sharma4
Institute of Neurorestoratology, The Third Medical Centre, Chinese PLA General Hospital, Beijing 100853, China
Beijing Hongtianji Neuroscience Academy, Beijing 100144, China
Department of Neurosurgery, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine Beijing 100007, China
Int. Exp. CNS Injury & Repair, Neurobiology (MRC) & Neuroanatomy (UU), Uppsala University, University Hospital, Anesthesiology & Intensive Care Medicine, Dept. Surgical Sciences, Uppsala, Sweden

Abstract

Clinical cell therapies (CTs) for neurological diseases and cellular damage have been explored for more than 2 decades. According to the United States Food and Drug Administration, there are 2 types of cell categories for therapy, namely stem cell-derived CT products and mature/functionally differentiated cell-derived CT products. However, regardless of the type of CT used, the majority of reports of clinical CTs from either small sample sizes based on single-center phase 1 or 2 unblinded trials or retrospective clinical studies showed effects on neurological improvement and the ability to either partially or temporarily thwart the deteriorating cellular processes of the neurodegenerative diseases. There have been only a few prospective, multicenter, randomized, double- blind placebo-control clinical trials of CTs so far in this developing novel area that have shown negative results, and more clinical trials are needed. This will expand our knowledge in exploring the type of cells that yield promising results and restore damaged neurological structure and functions of the central nervous system based on higher level evidence-based medical data. In this review, we briefly introduce the developmental process, current state, and future prospective for clinical neurorestorative CT.

Keywords: olfactory ensheathing cells, cell therapy, mature/functional cells, neurorestoration, stem cell-derived cell therapy product

References(282)

[1]
D Kondziolka, L Wechsler, S Goldstein, et al. Transplantation of cultured human neuronal cells for patients with stroke. Neurology. 2000, 55(4): 565-569.
DOI Google Scholar
[2]
D Kondziolka, GK Steinberg, L Wechsler, et al. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg. 2005, 103(1): 38-45.
DOI Google Scholar
[3]
SI Savitz, J Dinsmore, JL Wu, et al. Neurotrans- plantation of fetal porcine cells in patients with basal Ganglia infarcts: a preliminary safety and feasibility study. Cerebrovasc Dis. 2005, 20(2): 101-107.
DOI Google Scholar
[4]
EH Holbrook, EM Wu, WT Curry, et al. Immunohistochemical characterization of human olfactory tissue. Laryngoscope. 2011, 121(8): 1687-1701.
DOI Google Scholar
[5]
W Lu, D Duan, Z Ackbarkhan, et al. Differentiation of human olfactory mucosa mesenchymal stem cells into photoreceptor cells in vitro. Int J Ophthalmol. 2017, 10(10): 1504-1509.
Google Scholar
[6]
HY Huang, HM Wang, L Chen, et al. Influence factors for functional improvement after olfactory ensheathing cell transplantation for chronic spinal cord injury. Chin J Reparative Reconstr Surg. 2006, 20(4): 434-438.
Google Scholar
[7]
HY Huang, G Raisman, PR Sanberg, et al. Neuroresto- ratology. New York: Nova Biomedical, 2015.
[8]
HY Huang, HM Wang, B Xiu, et al. Preliminary report of clinical trial for olfactory ensheathing cell transplantation treating the spinal cord injury. J Navy General Hospital of PLA. 2002, 15(1): 18-21.
Google Scholar
[9]
HY Huang, L Chen, HM Wang, et al. Influence of patients' age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. Chin Med J. 2003, 116(10): 1488-1491.
Google Scholar
[10]
SS Rabinovich, VI Seledtsov, OV Poveschenko, et al. Transplantation treatment of spinal cord injury patients. Biomedecine Pharmacother. 2003, 57(9): 428-433.
DOI Google Scholar
[11]
J Guest, LP Herrera, T Qian. Rapid recovery of segmental neurological function in a tetraplegic patient following transplantation of fetal olfactory bulb-derived cells. Spinal Cord. 2006, 44(3): 135-142.
DOI Google Scholar
[12]
ZC Zhang, TS Sun, CQ Ye, et al. Treatment of thoracic spine and spinal cord injury (in Chinese). Chin J Rehabilit Theo Prac. 2006, 12(4): 336-338.
Google Scholar
[13]
ZC Zheng, C Liu, L Zhang, et al. Olfactory ensheathing cell transplantation in 106 patients with old spinal cord injury: Differences in ages, sexes, disease courses, injured types and sites. Neural Regen Res. 2007, 2(6): 380-384.
DOI Google Scholar
[14]
HY Huang, L Chen, HM Wang, et al. Safety of fetal olfactory ensheathing cell transplantation in patients with chronic spinal cord injury. A 38-month follow- up with MRI. Chin J Reparative Reconstr Surg. 2006, 20(4): 439-443.
Google Scholar
[15]
HY Huang, HT Xi, L Chen, et al. Long-term outcome of olfactory ensheathing cell therapy for patients with complete chronic spinal cord injury. Cell Transplant. 2012, 21(Suppl 1): S23-S31.
DOI Google Scholar
[16]
GF Bao, ZM Cui, WD Li, et al. Olfactory ensheathing cell transplantation in the treatment of spinal cord injury in 5 cases. J Clin Rehabilit Tissue Eng Res. 2007, 11(3): 512-514.
Google Scholar
[17]
ZC Zheng, C Liu, L Zhang, et al. Olfactory ensheathing cell transplantation in 106 patients with old spinal cord injury: Differences in ages, sexes, disease courses, injured types and sites. Neural Regen Res. 2007, 2(6): 380-384.
DOI Google Scholar
[18]
C Liu, ZC Zheng, R Gao, et al. Neurofunctional evaluation in spinal cord injury patients after olfactory ensheathing cell transplantation. J Clin Rehabilit Tissue Eng Res. 2008, 12(16): 3037-3040.
Google Scholar
[19]
ZC Zheng, C Liu, R Gao, et al. Influence of transplanting time on olfactory ensheathing cell transplantation for spinal cord injury. J Clin Rehabilit Tissue Eng Res. 2008, 12(3): 583-586.
Google Scholar
[20]
GV Seledtsova, SS Rabinovich, SN Belogorodtsev, et al. Delayed results of transplantation of fetal neurogenic tissue in patients with consequences of spinal cord trauma. Bull Exp Biol Med. 2010, 149(4): 530-533.
DOI Google Scholar
[21]
J Wu, TS Sun, CQ Ye, et al. Clinical observation of fetal olfactory ensheathing glia transplantation (OEGT) in patients with complete chronic spinal cord injury. Cell Transplant. 2012, 21(Suppl 1): S33-S37.
DOI Google Scholar
[22]
D Wang, X He, H Li, et al. Five years follow-up observation on patients with spinal cord injury treated with olfactory ensheathing cell transplantation. J Invest Med. 2013, 61(4): S5-S6.
Google Scholar
[23]
YJ Rao, WX Zhu, YX Guo, et al. Long-term outcome of olfactory ensheathing cell transplantation in six patients with chronic complete spinal cord injury. Cell Transplant. 2013, 22(Suppl 1): S21-S25.
DOI Google Scholar
[24]
YJ Rao, WX Zhu, HJ Liu, et al. Clinical application of olfactory ensheathing cells in the treatment of spinal cord injury. J Int Med Res. 2013, 41(2): 473-481.
DOI Google Scholar
[25]
P Tabakow, W Jarmundowicz, B Czapiga, et al. Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury. Cell Transplant. 2013, 22(9): 1591-1612.
DOI Google Scholar
[26]
P Tabakow, G Raisman, W Fortuna, et al. Functional regeneration of supraspinal connections in a patient with transected spinal cord following transplantation of bulbar olfactory ensheathing cells with peripheral nerve bridging. Cell Transplant. 2014, 23(12): 1631-1655.
DOI Google Scholar
[27]
ZC Zheng, GF Liu, YX Chen, et al. Olfactory ensheathing cell transplantation improves sympathetic skin responses in chronic spinal cord injury. Neural Regen Res. 2013, 8(30): 2849-2855.
Google Scholar
[28]
F Féron, C Perry, J Cochrane, et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain. 2005, 128(Pt 12): 2951-2960.
DOI Google Scholar
[29]
A Mackay-Sim, F Féron, J Cochrane, et al. Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial. Brain. 2008, 131(Pt 9): 2376-2386.
DOI Google Scholar
[30]
L Chen, YQ Zhang, XJ He, et al. Comparison of intramedullary transplantation of olfactory ensheathing cell for patients with chronic complete spinal cord injury worldwide. J Neurorestoratology. 2018, 6(1): 146-151.
DOI Google Scholar
[31]
C Lima, J Pratas-Vital, P Escada, et al. Olfactory mucosa autografts in human spinal cord injury: a pilot clinical study. J Spinal Cord Med. 2006, 29(3): 191-203; discussion 204-6.
DOI Google Scholar
[32]
C Lima, P Escada, J Pratas-Vital, et al. Olfactory mucosal autografts and rehabilitation for chronic traumatic spinal cord injury. Neurorehabil Neural Repair. 2010, 24(1): 10-22.
DOI Google Scholar
[33]
HS Chhabra, C Lima, S Sachdeva, et al. Autologous olfactory mucosal transplant in chronic spinal cord injury: an Indian pilot study. Spinal Cord. 2009, 47(12): 887-895.
DOI Google Scholar
[34]
S Wang, JK Lu, Y Li, et al. Autologous olfactory lamina propria transplantation for chronic spinal cord injury: three-year follow-up outcomes from a prospective double-blinded clinical trial. Cell Transplant. 2016, 25(1): 141-157.
DOI Google Scholar
[35]
BJ Dlouhy, O Awe, RC Rao, et al. Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient: Case report. J Neurosurg Spine. 2014, 21(4): 618-622.
DOI Google Scholar
[36]
SS Rabinovich, VI Seledtsov, NV Banul, et al. Cell therapy of brain stroke. Bull Exp Biol Med. 2005, 139(1): 126-128.
DOI Google Scholar
[37]
VI Seledtsov, MY Kafanova, SS Rabinovich, et al. Cell therapy of cerebral palsy. Bull Exp Biol Med. 2005, 139(4): 499-503.
DOI Google Scholar
[38]
VI Seledtsov, SS Rabinovich, OV Parlyuk, et al. Cell transplantation therapy in re-animating severely head-injured patients. Biomedecine Pharmacother. 2005, 59(7): 415-420.
DOI Google Scholar
[39]
VI Seledtsov, SS Rabinovich, EA Kashchenko, et al. Immunological and clinical aspects of cell therapy in the treatment of aftereffects of craniocerebral injury. Bull Exp Biol Med. 2006, 141(1): 121-123.
DOI Google Scholar
[40]
VI Seledtsov, SS Rabinovich, OV Parlyuk, et al. Cell therapy of comatose states. Bull Exp Biol Med. 2006, 142(1): 129-132.
DOI Google Scholar
[41]
HY Huang, L Chen, HT Xi, et al. Olfactory ensheathing cells transplantation for central nervous system diseases in 1, 255 patients (in Chinese). Chin J Reparative Reconstr Surg. 2009, 23(1): 14-20.
Google Scholar
[42]
L Chen, HY Huang, HT Xi, et al. Intracranial transplant of olfactory ensheathing cells in children and adolescents with cerebral palsy: a randomized controlled clinical trial. Cell Transplant. 2010, 19(2): 185-191.
DOI Google Scholar
[43]
L Chen, HY Huang, J Zhang, et al. Short-term outcome of olfactory ensheathing cells transplantation for treatment of amyotrophic lateral sclerosis. Chin J Reparative Reconstr Surg. 2007, 21(9): 961-966.
Google Scholar
[44]
HY Huang, L Chen, HT Xi, et al. Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study. Clin Transplant. 2008, 22(6): 710-718.
DOI Google Scholar
[45]
L Chen, D Chen, HT Xi, et al. Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateral sclerosis patients: benefits from multiple transplantations. Cell Transplant. 2012, 21(Suppl 1): S65-S77.
DOI Google Scholar
[46]
L Chen, HT Xi, HY Huang, et al. Multiple cell transplantation based on an intraparenchymal approach for patients with chronic phase stroke. Cell Transplant. 2013, 22(Suppl 1): S83-S91.
DOI Google Scholar
[47]
HT Xi, L Chen, HY Huang, et al. Preliminary report of multiple cell therapy for patients with multiple system atrophy. Cell Transplant. 2013, 22(Suppl 1): S93-S99.
DOI Google Scholar
[48]
HT Xi, D Chen. Cell-based neurorestorative therapy for postpoliomyelitis syndrome: a case report. J Neurorestoratology. 2016, 4: 45-50.
DOI Google Scholar
[49]
F Zhang, XZ Meng, F Lu, et al. Olfactory ensheathing cell transplantation for a patient with chronic sciatic nerve injury. J Neurorestoratology. 2017, 5: 1-4.
DOI Google Scholar
[50]
XL Guo, X Wang, Y Li, et al. Olfactory ensheathing cell transplantation improving cerebral infarction sequela: a case report and literature review. J Neurorestoratology. 2019, 7(2): 82-88.
DOI Google Scholar
[51]
E Syková, A Homola, R Mazanec, et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant. 2006, 15(8/9): 675-687.
DOI Google Scholar
[52]
ER Chernykh, VV Stupak, GM Muradov, et al. Application of autologous bone marrow stem cells in the therapy of spinal cord injury patients. Bull Exp Biol Med. 2007, 143(4): 543-547.
DOI Google Scholar
[53]
AF Cristante, TE Barros-Filho, N Tatsui, et al. Stem cells in the treatment of chronic spinal cord injury: evaluation of somatosensitive evoked potentials in 39 patients. Spinal Cord. 2009, 47(10): 733-738.
DOI Google Scholar
[54]
AA Kumar, SR Kumar, R Narayanan, et al. Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: a phase I/II clinical safety and primary efficacy data. Exp Clin Transplant. 2009, 7(4): 241-248.
Google Scholar
[55]
A Sharma, H Sane, D Khopkar, et al. Functional recovery in chronic stage of spinal cord injury by neurorestorative approach: a case report. Case Rep Surg. 2014, 2014: 404207.
DOI Google Scholar
[56]
H Zhu, W Poon, YS Liu, et al. Phase I-II clinical trial assessing safety and efficacy of umbilical cord blood mononuclear cell transplant therapy of chronic complete spinal cord injury. Cell Transplant. 2016, 25(11): 1925-1943.
DOI Google Scholar
[57]
Z Kakabadze, N Kipshidze, K Mardaleishvili, et al. Phase 1 trial of autologous bone marrow stem cell transplantation in patients with spinal cord injury. Stem Cells Int. 2016, 2016: 6768274.
DOI Google Scholar
[58]
NT Liem, VD Chinh, NT Thinh, et al. Improved bowel function in patients with spina bifida after bone marrow-derived mononuclear cell transplantation: a report of 2 cases. Am J Case Rep. 2018, 19: 1010-1018.
DOI Google Scholar
[59]
KI Papadopoulos, SS Low, TC Aw, et al. Safety and feasibility of autologous umbilical cord blood transfusion in 2 toddlers with cerebral palsy and the role of low dose granulocyte-colony stimulating factor injections. Restor Neurol Neurosci. 2011, 29(1): 17-22.
DOI Google Scholar
[60]
C Purandare, DG Shitole, V Belle, et al. Therapeutic potential of autologous stem cell transplantation for cerebral palsy. Case Rep Transplant. 2012, 2012: 825289.
DOI Google Scholar
[61]
A Sharma, N Gokulchandran, G Chopra, et al. Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life. Cell Transplant. 2012, 21(Suppl 1): S79-S90.
DOI Google Scholar
[62]
A Sharma, H Sane, A Paranjape, et al. Positron emission tomography-computer tomography scan used as a monitoring tool following cellular therapy in cerebral palsy and mental retardation-a case report. Case Rep Neurol Med. 2013, 2013: 141983.
DOI Google Scholar
[63]
A Sharma, H Sane, N Gokulchandran, et al. A clinical study of autologous bone marrow mononuclear cells for cerebral palsy patients: a new frontier. Stem Cells Int. 2015, 2015: 905874.
DOI Google Scholar
[64]
A Sharma, H Sane, N Gokulchandran, et al. An open-label proof-of-concept study of intrathecal autologous bone marrow mononuclear cell transplantation in intellectual disability. Stem Cell Res Ther. 2018, 9(1): 19.
DOI Google Scholar
[65]
A Jensen, E Hamelmann. First autologous cell therapy of cerebral palsy caused by hypoxic-ischemic brain damage in a child after cardiac arrest-individual treatment with cord blood. Case Rep Transplant. 2013, 2013: 951827.
DOI Google Scholar
[66]
C Mancías-Guerra, AR Marroquín-Escamilla, O González- Llano, et al. Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial. Cytotherapy. 2014, 16(6): 810-820.
DOI Google Scholar
[67]
WA El-Kheir, H Gabr, MR Awad, et al. Autologous bone marrow-derived cell therapy combined with physical therapy induces functional improvement in chronic spinal cord injury patients. Cell Transplant. 2014, 23(6): 729-745.
DOI Google Scholar
[68]
ZA Englander, J Sun, L Case, et al. Brain structural connectivity increases concurrent with functional improvement: Evidence from diffusion tensor MRI in children with cerebral palsy during therapy. Neuroimage: Clin. 2015, 7: 315-324.
DOI Google Scholar
[69]
H Bansal, L Singh, P Verma, et al. Administration of autologous bone marrow-derived stem cells for treatment of cerebral palsy patients: a proof of concept. J Stem Cells. 2016, 11(1): 37-49.
Google Scholar
[70]
KI Park, YH Lee, WJ Rah, et al. Effect of intravenous infusion of G-CSF-mobilized peripheral blood mononuclear cells on upper extremity function in cerebral palsy children. Ann Rehabil Med. 2017, 41(1): 113-120.
DOI Google Scholar
[71]
JM Sun, AW Song, LE Case, et al. Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: a randomized, placebo-controlled trial. Stem Cells Transl Med. 2017, 6(12): 2071-2078.
Google Scholar
[72]
LT Nguyen, AT Nguyen, CD Vu, et al. Outcomes of autologous bone marrow mononuclear cells for cerebral palsy: an open label uncontrolled clinical trial. BMC Pediatr. 2017, 17(1): 104.
DOI Google Scholar
[73]
TL Nguyen, HP Nguyen, TK Nguyen. The effects of bone marrow mononuclear cell transplantation on the quality of life of children with cerebral palsy. Health Qual Life Outcomes. 2018, 16(1): 164.
DOI Google Scholar
[74]
E Chernykh, E Shevela, M Kafanova, et al. Monocyte- derived macrophages for treatment of cerebral palsy: a study of 57 cases. J Neurorestor- atology. 2018, 6: 41-47.
DOI Google Scholar
[75]
WJ Rah, YH Lee, JH Moon, et al. Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood stem cells in children with cerebral palsy: a randomized, double-blind, cross-over study. J Transl Med. 2017, 15(1): 16.
DOI Google Scholar
[76]
CS Cox Jr, JE Baumgartner, MT Harting, et al. Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children. Neurosurgery. 2011, 68(3): 588-600.
DOI Google Scholar
[77]
GP Liao, MT Harting, RA Hetz, et al. Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children. Pediatr Crit Care Med. 2015, 16(3): 245-255.
DOI Google Scholar
[78]
CS Cox Jr, RA Hetz, GP Liao, et al. Treatment of severe adult traumatic brain injury using bone marrow mononuclear cells. Stem Cells. 2017, 35(4): 1065-1079.
DOI Google Scholar
[79]
A Sharma, H Sane, P Kulkarni, et al. Cell therapy attempted as a novel approach for chronic traumatic brain injury - a pilot study. Springerplus. 2015, 4: 26.
DOI Google Scholar
[80]
ML Mendonça, GR Freitas, SA Silva, et al. Safety of intra-arterial autologous bone marrow mononuclear cell transplantation for acute ischemic stroke. Arq Bras Cardiol. 2006, 86(1): 52-55.
Google Scholar
[81]
V Battistella, GR de Freitas, LM da Fonseca, et al. Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke. Regen Med. 2011, 6(1): 45-52.
DOI Google Scholar
[82]
SI Savitz, V Misra, M Kasam, et al. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011, 70(1): 59-69.
DOI Google Scholar
[83]
ME Haque, RE Gabr, SD George, et al. Serial cerebral metabolic changes in patients with ischemic stroke treated with autologous bone marrow derived mononuclear cells. Front Neurol. 2019, 10: 141.
DOI Google Scholar
[84]
K Prasad, S Mohanty, R Bhatia, et al. Autologous intravenous bone marrow mononuclear cell therapy for patients with subacute ischaemic stroke: a pilot study. Indian J Med Res. 2012, 136(2): 221-228.
Google Scholar
[85]
A Bhasin, MV Srivastava, SS Kumaran, et al. Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc Dis Extra. 2011, 1(1): 93-104.
DOI Google Scholar
[86]
A Bhasin, M Srivastava, R Bhatia, et al. Autologous intravenous mononuclear stem cell therapy in chronic ischemic stroke. J Stem Cells Regen Med. 2012, 8(3): 181-189.
DOI Google Scholar
[87]
A Bhasin, MV Srivastava, S Mohanty, et al. Stem cell therapy: a clinical trial of stroke. Clin Neurol Neurosurg. 2013, 115(7): 1003-1008.
DOI Google Scholar
[88]
A Bhasin, SS Kumaran, R Bhatia, et al. Safety and feasibility of autologous mesenchymal stem cell transplantation in chronic stroke in Indian patients. A four-year follow up. J Stem Cells Regen Med. 2017, 13(1): 14-19.
DOI Google Scholar
[89]
MA Friedrich, MP Martins, MD Araújo, et al. Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke. Cell Transplant. 2012, 21(Suppl 1): S13-S21.
DOI Google Scholar
[90]
A Vasconcelos-dos-Santos, PH Rosado-de-Castro, SA Lopes de Souza, et al. Intravenous and intra-arterial administration of bone marrow mononuclear cells after focal cerebral ischemia: Is there a difference in biodistribution and efficacy? Stem Cell Res. 2012, 9(1): 1-8.
DOI Google Scholar
[91]
F Moniche, A Gonzalez, JR Gonzalez-Marcos, et al. Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial. Stroke. 2012, 43(8): 2242-2244.
DOI Google Scholar
[92]
F Moniche, PH Rosado-de-Castro, I Escudero, et al. Increasing dose of autologous bone marrow mononuclear cells transplantation is related to stroke outcome: results from a pooled analysis of two clinical trials. Stem Cells Int. 2016, 2016: 8657173.
DOI Google Scholar
[93]
F Moniche, I Escudero, E Zapata-Arriaza, et al. Intra-arterial bone marrow mononuclear cells (BM-MNCs) transplantation in acute ischemic stroke (IBIS trial): protocol of a phase II, randomized, dose-finding, controlled multicenter trial. Int J Stroke. 2015, 10(7): 1149-1152.
DOI Google Scholar
[94]
A Sharma, H Sane, A Nagrajan, et al. Autologous bone marrow mononuclear cells in ischemic cerebrovascular accident paves way for neurorestoration: a case report. Case Rep Med. 2014, 2014: 530239.
DOI Google Scholar
[95]
A Sharma, H Sane, N Gokulchandran, et al. Autologous bone marrow mononuclear cells intrathecal transplanta- tion in chronic stroke. Stroke Res Treat. 2014, 2014: 234095.
DOI Google Scholar
[96]
A Taguchi, C Sakai, T Soma, et al. Intravenous autologous bone marrow mononuclear cell transplantation for stroke: Phase1/2a clinical trial in a homogeneous group of stroke patients. Stem Cells Dev. 2015, 24(19): 2207-2218.
DOI Google Scholar
[97]
ER Chernykh, EY Shevela, NM Starostina, et al. Safety and therapeutic potential of M2 macrophages in stroke treatment. Cell Transplant. 2016, 25(8): 1461-1471.
DOI Google Scholar
[98]
DT Laskowitz, ER Bennett, RJ Durham, et al. Allogeneic umbilical cord blood infusion for adults with ischemic stroke: clinical outcomes from a phase I safety study. Stem Cells Transl Med. 2018, 7(7): 521-529.
DOI Google Scholar
[99]
AMA Hammadi, F Alhimyari. Intra-arterial injection of autologous bone marrow-derived mononuclear cells in ischemic stroke patients. Exp Clin Transplant. 2019, 17(Suppl 1): 239-241.
DOI Google Scholar
[100]
K Prasad, A Sharma, A Garg, et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke. 2014, 45(12): 3618-3624.
DOI Google Scholar
[101]
SI Savitz, D Yavagal, G Rappard, et al. A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow-derived ALD-401 cells in patients with recent stable ischemic stroke (RECOVER-stroke). Circulation. 2019, 139(2): 192-205.
DOI Google Scholar
[102]
A Sharma, H Sane, P Badhe, et al. A clinical study shows safety and efficacy of autologous bone marrow mononuclear cell therapy to improve quality of life in muscular dystrophy patients. Cell Transplant. 2013, 22(Suppl 1): S127-S138.
DOI Google Scholar
[103]
A Sharma, A Paranjape, H Sane, et al. Cellular transplantation alters the disease progression in becker's muscular dystrophy. Case Rep Transplant. 2013, 2013: 909328.
DOI Google Scholar
[104]
A Sharma, H Sane, A Paranjape, et al. Autologous bone marrow mononuclear cell transplantation in Duchenne muscular dystrophy - a case report. Am J Case Rep. 2014, 15: 128-134.
DOI Google Scholar
[105]
A Sharma, H Sane, N Gokulchandra, et al. Effect of cellular therapy in progression of becker's muscular dystrophy: a case study. Eur J Transl Myol. 2016, 26(1): 5522.
DOI Google Scholar
[106]
A Sharma, N Gokulchandran, H Sane, et al. Autologous bone marrow mononuclear cell therapy for autism: an open label proof of concept study. Stem Cells Int. 2013, 2013: 623875.
DOI Google Scholar
[107]
AK Sharma, HM Sane, AA Paranjape, et al. The effect of autologous bone marrow mononuclear cell transplantation on the survival duration in Amyotrophic Lateral Sclerosis-a retrospective controlled study. Am J Stem Cells. 2015, 4(1): 50-65.
Google Scholar
[108]
A Sharma, H Sane, N Gokulchandran, et al. Cellular therapy for chronic traumatic brachial plexus injury. Adv Biomed Res. 2018, 7: 51.
DOI Google Scholar
[109]
S Hogendoorn, BJ Duijnisveld, SG van Duinen, et al. Local injection of autologous bone marrow cells to regenerate muscle in patients with traumatic brachial plexus injury: a pilot study. Bone Joint Res. 2014, 3(2): 38-47.
DOI Google Scholar
[110]
EM Horwitz, K Le Blanc, M Dominici, et al. Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. Cytotherapy. 2005, 7(5): 393-395.
DOI Google Scholar
[111]
M Dominici, K Le Blanc, I Mueller, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8(4): 315-317.
DOI Google Scholar
[112]
J Galipeau, M Krampera, J Barrett, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016, 18(2): 151-159.
DOI Google Scholar
[113]
L Mazzini, F Fagioli, R Boccaletti, et al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003, 4(3): 158-161.
DOI Google Scholar
[114]
L Mazzini, I Ferrero, V Luparello, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. Exp Neurol. 2010, 223(1): 229-237.
DOI Google Scholar
[115]
L Mazzini, K Mareschi, I Ferrero, et al. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol Res. 2006, 28(5): 523-526.
DOI Google Scholar
[116]
D Karussis, C Karageorgiou, A Vaknin-Dembinsky, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010, 67(10): 1187-1194.
DOI Google Scholar
[117]
M Blanquer, MA Pérez Espejo, F Iniesta, et al. Bone marrow stem cell transplantation in amyotrophic lateral sclerosis: technical aspects and preliminary results from a clinical trial. Methods Find Exp Clin Pharmacol. 2010, 32(Suppl A): 31-37.
Google Scholar
[118]
M Blanquer, JM Moraleda, F Iniesta, et al. Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study. Stem Cells. 2012, 30(6): 1277-1285.
DOI Google Scholar
[119]
S Prabhakar, R Rajan, R Sharma, et al. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: a pilot study. Neurol India. 2012, 60(5): 465.
DOI Google Scholar
[120]
W Baek, YS Kim, SH Koh, et al. Stem cell transplantation into the intraventricular space via an Ommaya reservoir in a patient with amyotrophic lateral sclerosis. J Neurosurg Sci. 2012, 56(3): 261-263.
Google Scholar
[121]
KW Oh, C Moon, HY Kim, et al. Phase I trial of repeated intrathecal autologous bone marrow- derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl Med. 2015, 4(6): 590-597.
DOI Google Scholar
[122]
M Canesi, R Giordano, L Lazzari, et al. Finding a new therapeutic approach for no-option Parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy. J Transl Med. 2016, 14(1): 127.
DOI Google Scholar
[123]
P Petrou, Y Gothelf, Z Argov, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 2016, 73(3): 337-344.
DOI Google Scholar
[124]
E Syková, P Rychmach, I Drahorádová, et al. Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: results of phase I/IIa clinical trial. Cell Transplant. 2017, 26(4): 647-658.
DOI Google Scholar
[125]
J Gamez, F Carmona, N Raguer, et al. Cellular transplants in amyotrophic lateral sclerosis patients: an observational study. Cytotherapy. 2010, 12(5): 669-677.
DOI Google Scholar
[126]
OY Bang, JS Lee, PH Lee, et al. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005, 57(6): 874-882.
DOI Google Scholar
[127]
C Suárez-Monteagudo, P Hernández-Ramírez, L Alvarez- González, et al. Autologous bone marrow stem cell neurotransplantation in stroke patients. An open study. Restor Neurol Neurosci. 2009, 27(3): 151-161.
Google Scholar
[128]
JS Lee, JM Hong, GJ Moon, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010, 28(6): 1099-1106.
DOI Google Scholar
[129]
O Honmou, K Houkin, T Matsunaga, et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain. 2011, 134(Pt 6): 1790-1807.
DOI Google Scholar
[130]
YJ Jiang, WS Zhu, JH Zhu, et al. Feasibility of delivering mesenchymal stem cells via catheter to the proximal end of the lesion artery in patients with stroke in the territory of the middle cerebral artery. Cell Transplant. 2013, 22(12): 2291-2298.
DOI Google Scholar
[131]
KS Tsang, CPS Ng, XL Zhu, et al. Phase I/II randomized controlled trial of autologous bone marrow-derived mesenchymal stem cell therapy for chronic stroke. World J Stem Cells. 2017, 9(8): 133-143.
DOI Google Scholar
[132]
ML Levy, JR Crawford, N Dib, et al. Phase I/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke. Stroke. 2019, 50(10): 2835-2841.
DOI Google Scholar
[133]
DC Hess, LR Wechsler, WM Clark, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017, 16(5): 360-368.
DOI Google Scholar
[134]
DC Hess, CA Sila, AJ Furlan, et al. A double-blind placebo-controlled clinical evaluation of MultiStem for the treatment of ischemic stroke. Int J Stroke. 2014, 9(3): 381-386.
DOI Google Scholar
[135]
T Osanai, K Houkin, S Uchiyama, et al. Treatment evaluation of acute stroke for using in regenerative cell elements (TREASURE) trial: Rationale and design. Int J Stroke. 2018, 13(4): 444-448.
DOI Google Scholar
[136]
KS Kang, SW Kim, YH Oh, et al. A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved sensory perception and mobility, both functionally and morphologically: a case study. Cytotherapy. 2005, 7(4): 368-373.
DOI Google Scholar
[137]
LF Geffner, P Santacruz, M Izurieta, et al. Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. Cell Transplant. 2008, 17(12): 1277-1293.
DOI Google Scholar
[138]
JH Park, DY Kim, IY Sung, et al. Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans. Neurosurgery. 2012, 70(5): 1238-1247.
DOI Google Scholar
[139]
R Pal, NK Venkataramana, A Bansal, et al. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: a pilot clinical study. Cytotherapy. 2009, 11(7): 897-911.
DOI Google Scholar
[140]
NA Kishk, H Gabr, S Hamdy, et al. Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury. Neurorehabil Neural Repair. 2010, 24(8): 702-708.
DOI Google Scholar
[141]
J Liu, DM Han, ZD Wang, et al. Clinical analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells. Cytotherapy. 2013, 15(2): 185-191.
DOI Google Scholar
[142]
GH Dai, XB Liu, Z Zhang, et al. Transplantation of autologous bone marrow mesenchymal stem cells in the treatment of complete and chronic cervical spinal cord injury. Brain Res. 2013, 1533: 73-79.
DOI Google Scholar
[143]
MV Mendonça, TF Larocca, BS de Freitas Souza, et al. Safety and neurological assessments after autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury. Stem Cell Res Ther. 2014, 5(6): 126.
DOI Google Scholar
[144]
HS Satti, A Waheed, P Ahmed, et al. Autologous mesenchymal stromal cell transplantation for spinal cord injury: a phase I pilot study. Cytotherapy. 2016, 18(4): 518-522.
DOI Google Scholar
[145]
JW Hur, TH Cho, DH Park, et al. Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: a human trial. J Spinal Cord Med. 2016, 39(6): 655-664.
DOI Google Scholar
[146]
TF Larocca, CT Macêdo, BSF Souza, et al. Image-guided percutaneous intralesional administration of mesenchymal stromal cells in subjects with chronic complete spinal cord injury: a pilot study. Cytotherapy. 2017, 19(10): 1189-1196.
DOI Google Scholar
[147]
H Guadalajara Labajo, M León Arellano, J Vaquero Crespo, et al. Objective demonstration of improvement of neurogenic bowel dysfunction in a case of spinal cord injury following stem cell therapy. J Surg Case Rep. 2018, 2018(11): rjy300.
DOI Google Scholar
[148]
AJ Santamaría, FD Benavides, DL DiFede, et al. Clinical and neurophysiological changes after targeted intrathecal injections of bone marrow stem cells in a C3 tetraplegic subject. J Neurotrauma. 2019, 36(3): 500-516.
DOI Google Scholar
[149]
A Chotivichit, M Ruangchainikom, P Chiewvit, et al. Chronic spinal cord injury treated with transplanted autologous bone marrow-derived mesenchymal stem cells tracked by magnetic resonance imaging: a case report. J Med Case Rep. 2015, 9: 79.
DOI Google Scholar
[150]
SK Oh, KH Choi, JY Yoo, et al. A phase III clinical trial showing limited efficacy of autologous mesenchymal stem cell therapy for spinal cord injury. Neurosurgery. 2016, 78(3): 436-447.
DOI Google Scholar
[151]
J Vaquero, M Zurita, MA Rico, et al. An approach to personalized cell therapy in chronic complete paraplegia: The Puerta de Hierro phase I/II clinical trial. Cytotherapy. 2016, 18(8): 1025-1036.
DOI Google Scholar
[152]
J Vaquero, M Zurita, C Bonilla, et al. Progressive increase in brain glucose metabolism after intrathecal administration of autologous mesenchymal stromal cells in patients with diffuse axonal injury. Cytotherapy. 2017, 19(1): 88-94.
DOI Google Scholar
[153]
J Vaquero, M Zurita, MA Rico, et al. Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury. Cytotherapy. 2017, 19(3): 349-359.
DOI Google Scholar
[154]
J Vaquero, M Zurita, MA Rico, et al. Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: Safety and efficacy of the 100/3 guideline. Cytotherapy. 2018, 20(6): 806-819.
Google Scholar
[155]
J Vaquero, M Zurita, MA Rico, et al. Intrathecal administration of autologous bone marrow stromal cells improves neuropathic pain in patients with spinal cord injury. Neurosci Lett. 2018, 670: 14-18.
DOI Google Scholar
[156]
J Vaquero, M Zurita, MA Rico, et al. Cell therapy with autologous mesenchymal stromal cells in post-traumatic syringomyelia. Cytotherapy. 2018, 20(6): 796-805.
DOI Google Scholar
[157]
J Vaquero, M Zurita, J Mucientes, et al. Intrathecal cell therapy with autologous stromal cells increases cerebral glucose metabolism and can offer a new approach to the treatment of Alzheimer's type dementia. Cytotherapy. 2019, 21(4): 428-432.
DOI Google Scholar
[158]
DM Han, J Liu, M Xue, et al. Clinical analysis of the treatment of spinocerebellar ataxia and multiple system atrophy-cerebellar type with umbilical cord mesenchymal stromal cells. Cytotherapy. 2011, 13(8): 913-917.
DOI Google Scholar
[159]
JL Jin, Z Liu, ZJ Lu, et al. Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spinocerebellar ataxia. Curr Neurovasc Res. 2013, 10(1): 11-20.
DOI Google Scholar
[160]
P Connick, M Kolappan, C Crawley, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012, 11(2): 150-156.
DOI Google Scholar
[161]
ZL Hou, Y Liu, XH Mao, et al. Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis. Cell Adh Migr. 2013, 7(5): 404-407.
DOI Google Scholar
[162]
S Wang, HB Cheng, GH Dai, et al. Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury. Brain Res. 2013, 1532: 76-84.
DOI Google Scholar
[163]
CL Tian, XW Wang, XD Wang, et al. Autologous bone marrow mesenchymal stem cell therapy in the subacute stage of traumatic brain injury by lumbar puncture. Exp Clin Transplant. 2013, 11(2): 176-181.
DOI Google Scholar
[164]
LM Wang, HJ Ji, JJ Zhou, et al. Therapeutic potential of umbilical cord mesenchymal stromal cells transplantation for cerebral palsy: a case report. Case Rep Transplant. 2013, 2013: 146347.
DOI Google Scholar
[165]
XD Wang, HB Cheng, RR Hua, et al. Effects of bone marrow mesenchymal stromal cells on gross motor function measure scores of children with cerebral palsy: a preliminary clinical study. Cytotherapy. 2013, 15(12): 1549-1562.
DOI Google Scholar
[166]
XD Wang, HZ Hu, RR Hua, et al. Effect of umbilical cord mesenchymal stromal cells on motor functions of identical twins with cerebral palsy: pilot study on the correlation of efficacy and hereditary factors. Cytotherapy. 2015, 17(2): 224-231.
DOI Google Scholar
[167]
H Bansal, L Singh, P Verma, et al. Administration of autologous bone marrow-derived stem cells for treatment of cerebral palsy patients: a proof of concept. J Stem Cells. 2016, 11(1): 37-49.
Google Scholar
[168]
L Huang, C Zhang, JW Gu, et al. A randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy. Cell Transplant. 2018, 27(2): 325-334.
DOI Google Scholar
[169]
MT Numan, A Kamdar, J Young, et al. Autologous adipose stem cell therapy for autonomic nervous system dysfunction in two young patients. Stem Cells Dev. 2017, 26(6): 391-393.
DOI Google Scholar
[170]
FD Lublin, JD Bowen, J Huddlestone, et al. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Mult Scler Relat Disord. 2014, 3(6): 696-704.
DOI Google Scholar
[171]
J Riley, T Federici, M Polak, et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes. Neurosurgery. 2012, 71(2): 405-416.
DOI Google Scholar
[172]
JD Glass, NM Boulis, K Johe, et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells. 2012, 30(6): 1144-1151.
DOI Google Scholar
[173]
J Riley, J Glass, EL Feldman, et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes. Neurosurgery. 2014, 74(1): 77-87.
DOI Google Scholar
[174]
EL Feldman, NM Boulis, J Hur, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol. 2014, 75(3): 363-373.
DOI Google Scholar
[175]
SA Goutman, MB Brown, JD Glass, et al. Long-term phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Ann Clin Transl Neurol. 2018, 5(6): 730-740.
DOI Google Scholar
[176]
JD Glass, VS Hertzberg, NM Boulis, et al. Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials. Neurology. 2016, 87(4): 392-400.
DOI Google Scholar
[177]
WQ Ren, F Yin, JN Zhang, et al. Neural stem cell transplantation for the treatment of primary torsion dystonia: a case report. Exp Ther Med. 2016, 12(2): 661-666.
DOI Google Scholar
[178]
Y Liu, SJ Chen, SY Li, et al. Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients. Stem Cell Res Ther. 2017, 8(1): 209.
DOI Google Scholar
[179]
H Saberi, P Moshayedi, HR Aghayan, et al. Treatment of chronic thoracic spinal cord injury patients with autologous Schwann cell transplantation: an interim report on safety considerations and possible outcomes. Neurosci Lett. 2008, 443(1): 46-50.
DOI Google Scholar
[180]
H Saberi, M Firouzi, Z Habibi, et al. Safety of intramedullary Schwann cell transplantation for postrehabilitation spinal cord injuries: 2-year follow-up of 33 cases. J Neurosurg Spine. 2011, 15(5): 515-525.
DOI Google Scholar
[181]
XH Zhou, GZ Ning, SQ Feng, et al. Transplantation of autologous activated Schwann cells in the treatment of spinal cord injury: six cases, more than five years of follow-up. Cell Transplant. 2012, 21(Suppl 1): S39-S47.
DOI Google Scholar
[182]
CG van Horne, JE Quintero, JT Slevin, et al. Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson's disease during deep brain stimulation surgery: 1-year follow-up study of safety, feasibility, and clinical outcome. J Neurosurg. 2018, 129(6): 1550-1561.
DOI Google Scholar
[183]
XF Yang, YF Xu, YB Zhang, et al. Functional improvement of patients with progressive muscular dystrophy by bone marrow and umbilical cord blood mesenchymal stem cell transplantations (in Chinese). Zhonghua Yi Xue Za Zhi. 2009, 89(36): 2552-2556.
Google Scholar
[184]
YT Lv, Y Zhang, M Liu, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med. 2013, 11: 196.
DOI Google Scholar
[185]
SO Yazdani, M Hafizi, AR Zali, et al. Safety and possible outcome assessment of autologous Schwann cell and bone marrow mesenchymal stromal cell co-transplantation for treatment of patients with chronic spinal cord injury. Cytotherapy. 2013, 15(7): 782-791.
DOI Google Scholar
[186]
S Oraee-Yazdani, M Hafizi, A Atashi, et al. Co- transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome. Spinal Cord. 2016, 54(2): 102-109.
DOI Google Scholar
[187]
L Chen, HY Huang, HT Xi, et al. A prospective randomized double-blind clinical trial using a combination of olfactory ensheathing cells and Schwann cells for the treatment of chronic complete spinal cord injuries. Cell Transplant. 2014, 23(Suppl 1): S35-S44.
DOI Google Scholar
[188]
ZF Xiao, FW Tang, JG Tang, et al. One-year clinical study of NeuroRegen scaffold implantation following scar resection in complete chronic spinal cord injury patients. Sci China Life Sci. 2016, 59(7): 647-655.
DOI Google Scholar
[189]
YN Zhao, FW Tang, ZF Xiao, et al. Clinical study of NeuroRegen scaffold combined with human mesenchymal stem cells for the repair of chronic complete spinal cord injury. Cell Transplant. 2017, 26(5): 891-900.
DOI Google Scholar
[190]
ZF Xiao, FW Tang, YN Zhao, et al. Significant improvement of acute complete spinal cord injury patients diagnosed by a combined criteria implanted with NeuroRegen scaffolds and mesenchymal stem cells. Cell Transplant. 2018, 27(6): 907-915.
DOI Google Scholar
[191]
XB Liu, XJ Fu, GH Dai, et al. Comparative analysis of curative effect of bone marrow mesenchymal stem cell and bone marrow mononuclear cell transplantation for spastic cerebral palsy. J Transl Med. 2017, 15(1): 48.
DOI Google Scholar
[192]
GA Moviglia, MT Moviglia Brandolino, D Couto, et al. Local immunomodulation and muscle progenitor cells induce recovery in atrophied muscles in spinal cord injury patients. J Neurorestoratology. 2018, 6(1): 136-145.
DOI Google Scholar
[193]
A Fassas, A Anagnostopoulos, A Kazis, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1997, 20(8): 631-638.
DOI Google Scholar
[194]
A Fassas, A Anagnostopoulos, A Kazis, et al. Autologous stem cell transplantation in progressive multiple sclerosis——an interim analysis of efficacy. J Clin Immunol. 2000, 20(1): 24-30.
Google Scholar
[195]
A Fassas, JR Passweg, A Anagnostopoulos, et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol. 2002, 249(8): 1088-1097.
DOI Google Scholar
[196]
RK Burt, AE Traynor, R Pope, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood. 1998, 92(10): 3505-3514.
DOI Google Scholar
[197]
RK Burt, AE Traynor, B Cohen, et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant. 1998, 21(6): 537-541.
DOI Google Scholar
[198]
RK Burt, BA Cohen, E Russell, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. 2003, 102(7): 2373-2378.
DOI Google Scholar
[199]
RK Burt, Y Loh, B Cohen, et al. Autologous non- myeloablative haemopoietic stem cell transplan- tation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009, 8(3): 244-253.
DOI Google Scholar
[200]
RK Burt, R Balabanov, XQ Han, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2015, 313(3): 275-284.
DOI Google Scholar
[201]
RK Burt, R Balabanov, J Burman, et al. Effect of nonmyeloablative hematopoietic stem cell transplan- tation vs continued disease-modifying therapy on disease progression in patients with relapsing- remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019, 321(2): 165-174.
DOI Google Scholar
[202]
RA Nash, JD Bowen, PA McSweeney, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003, 102(7): 2364-2372.
DOI Google Scholar
[203]
RA Nash, PA McSweeney, LJ Crofford, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood. 2007, 110(4): 1388-1396.
Google Scholar
[204]
JD Bowen, GH Kraft, A Wundes, et al. Autologous hematopoietic cell transplantation following high- dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant. 2012, 47(7): 946-951.
DOI Google Scholar
[205]
RA Nash, GJ Hutton, MK Racke, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing- remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015, 72(2): 159-169.
DOI Google Scholar
[206]
RA Nash, GJ Hutton, MK Racke, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017, 88(9): 842-852.
DOI Google Scholar
[207]
D Farge, M Labopin, A Tyndall, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2010, 95(2): 284-292.
DOI Google Scholar
[208]
A Fassas, VK Kimiskidis, I Sakellari, et al. Long- term results of stem cell transplantation for MS: a single-center experience. Neurology. 2011, 76(12): 1066-1070.
DOI Google Scholar
[209]
PA Muraro, M Pasquini, HL Atkins, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol. 2017, 74(4): 459-469.
DOI Google Scholar
[210]
M Rabusin, M Andolina, N Maximova, et al. Immunoablation followed by autologous hemato- poietic stem cell infusion for the treatment of severe autoimmune disease. Haematologica. 2000, 85(11 Suppl): 81-85.
Google Scholar
[211]
H Openshaw, BT Lund, A Kashyap, et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant. 2000, 6(5A): 563-575.
DOI Google Scholar
[212]
E Carreras, A Saiz, P Marín, et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica. 2003, 88(3): 306-314.
DOI Google Scholar
[213]
A Saiz, Y Blanco, E Carreras, et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology. 2004, 62(2): 282-284.
DOI Google Scholar
[214]
R Saccardi, GL Mancardi, A Solari, et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood. 2005, 105(6): 2601-2607.
DOI Google Scholar
[215]
R Saccardi, T Kozak, C Bocelli-Tyndall, et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler. 2006, 12(6): 814-823.
DOI Google Scholar
[216]
E Portaccio, MP Amato, G Siracusa, et al. Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. Mult Scler. 2007, 13(5): 676-678.
DOI Google Scholar
[217]
J Xu, BX Ji, L Su, et al. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis. Chin Med J. 2006, 119(22): 1851-1855.
DOI Google Scholar
[218]
L Su, J Xu, BX Ji, et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int J Hematol. 2006, 84(3): 276-281.
DOI Google Scholar
[219]
J Xu, BX Ji, L Su, et al. Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. Ann Hematol. 2011, 90(3): 343-348.
DOI Google Scholar
[220]
U Ergene, S Cağirgan, M Pehlivan, et al. WITHDRAWN: Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT). Transfus Apher Sci. 2006, 36(1): 23-29.
DOI Google Scholar
[221]
L Roccatagliata, M Rocca, P Valsasina, et al. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Mult Scler. 2007, 13(8): 1068-1070.
DOI Google Scholar
[222]
I Metz, CF Lucchinetti, H Openshaw, et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain. 2007, 130(Pt 5): 1254-1262.
DOI Google Scholar
[223]
J Fagius, J Lundgren, G Oberg. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler. 2009, 15(2): 229-237.
DOI Google Scholar
[224]
JQ Lu, JT Joseph, RA Nash, et al. Neuroinflamm- ation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation. Arch Neurol. 2010, 67(6): 716-722.
DOI Google Scholar
[225]
E Krasulová, M Trneny, T Kozák, et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler. 2010, 16(6): 685-693.
DOI Google Scholar
[226]
B Chen, M Zhou, J Ouyang, et al. Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. Neurol Sci. 2012, 33(4): 881-886.
DOI Google Scholar
[227]
GL Mancardi, MP Sormani, M Di Gioia, et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler. 2012, 18(6): 835-842.
DOI Google Scholar
[228]
JD Bowen, GH Kraft, A Wundes, et al. Autologous hematopoietic cell transplantation following high- dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant. 2012, 47(7): 946-951.
DOI Google Scholar
[229]
YL Shevchenko, AA Novik, AN Kuznetsov, et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol. 2008, 36(8): 922-928.
DOI Google Scholar
[230]
JL Shevchenko, AN Kuznetsov, TI Ionova, et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol. 2012, 40(11): 892-898.
DOI Google Scholar
[231]
JL Shevchenko, AN Kuznetsov, TI Ionova, et al. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives. Ann Hematol. 2015, 94(7): 1149-1157.
DOI Google Scholar
[232]
J Burman, E Iacobaeus, A Svenningsson, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry. 2014, 85(10): 1116-1121.
DOI Google Scholar
[233]
R Greco, A Bondanza, MC Oliveira, et al. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party. Mult Scler. 2015, 21(2): 189-197.
DOI Google Scholar
[234]
D Curro', L Vuolo, F Gualandi, et al. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: a MRI-based clinical study. Mult Scler. 2015, 21(11): 1423-1430.
DOI Google Scholar
[235]
HL Atkins, M Bowman, D Allan, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016, 388(10044): 576-585.
DOI Google Scholar
[236]
D Obradović, L Tukić, S Radovinović-Tasić, et al. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis——A 10-year follow-up of the first transplanted patient. Vojnosanit Pregl. 2016, 73(5): 504-508.
DOI Google Scholar
[237]
B Casanova, I Jarque, F Gascón, et al. Autologous hematopoietic stem cell transplantation in relapsing- remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. Neurol Sci. 2017, 38(7): 1213-1221.
DOI Google Scholar
[238]
J Frau, M Carai, G Coghe, et al. Long-term follow- up more than 10 years after HSCT: a monocentric experience. J Neurol. 2018, 265(2): 410-416.
DOI Google Scholar
[239]
JJ Moore, JC Massey, CD Ford, et al. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019, 90(5): 514-521.
DOI Google Scholar
[240]
A Mariottini, C Innocenti, B Forci, et al. Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis. Eur J Neurol. 2019, 26(4): 624-630.
DOI Google Scholar
[241]
A Saiz, Y Blanco, J Berenguer, et al. Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurologia. 2008, 23(7): 405-407.
Google Scholar
[242]
R Saccardi, MS Freedman, MP Sormani, et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler. 2012, 18(6): 825-834.
DOI Google Scholar
[243]
C Zhang, HY Feng, SL Huang, et al. Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation (in Chinese). Chin J Med Genet. 2005, 22(4): 399-405.
Google Scholar
[244]
C Zhang, W Chen, LL Xiao, et al. Allogeneic umbilical cord blood stem cell transplantation in Duchenne muscular dystrophy (in Chinese). Zhonghua Yi Xue Za Zhi. 2005, 85(8): 522-525.
Google Scholar
[245]
H Deda, MC Inci, AE Kürekçi, et al. Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hematopoietic stem cell transplantation: 1-year follow-up. Cytotherapy. 2008, 10(6): 565-574.
DOI Google Scholar
[246]
H Deda, MC Inci, AE Kürekçi, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy. 2009, 11(1): 18-25.
DOI Google Scholar
[247]
SH Appel, JI Engelhardt, JS Henkel, et al. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008, 71(17): 1326-1334.
DOI Google Scholar
[248]
A Al-Zoubi, E Jafar, M Jamous, et al. Transplantation of purified autologous leukapheresis-derived CD34+ and CD133+ stem cells for patients with chronic spinal cord injuries: long-term evaluation of safety and efficacy. Cell Transplant. 2014, 23(Suppl 1): S25-S34.
DOI Google Scholar
[249]
N Sprigg, PM Bath, L Zhao, et al. Granulocyte- colony-stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: the Stem cell Trial of recovery EnhanceMent after Stroke (STEMS) pilot randomized, controlled trial (ISRCTN 16784092). Stroke. 2006, 37(12): 2979-2983.
DOI Google Scholar
[250]
S Boy, S Sauerbruch, M Kraemer, et al. Mobilisation of hematopoietic CD34+ precursor cells in patients with acute stroke is safe——results of an open- labeled non randomized phase I/II trial. PLoS One. 2011, 6(8): e23099.
DOI Google Scholar
[251]
LM Wang, HJ Ji, M Li, et al. Intrathecal administration of autologous CD34 positive cells in patients with past cerebral infarction: a safety study. ISRN Neurol. 2013, 2013: 128591.
DOI Google Scholar
[252]
DC Chen, SZ Lin, JR Fan, et al. Intracerebral implantation of autologous peripheral blood stem cells in stroke patients: a randomized phase II study. Cell Transplant. 2014, 23(12): 1599-1612.
DOI Google Scholar
[253]
PH Sung, HS Lin, WC Lin, et al. Intra-carotid arterial transfusion of autologous circulatory derived CD34+cells for old ischemic stroke patients-a phase I clinical trial to evaluate safety and tolerability. Am J Transl Res. 2018, 10(9): 2975-2989.
Google Scholar
[254]
CT Scott, D Magnus. Wrongful termination: lessons from the Geron clinical trial. Stem Cells Transl Med. 2014, 3(12): 1398-1401.
DOI Google Scholar
[255]
SD Schwartz, CD Regillo, BL Lam, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015, 385(9967): 509-516.
DOI Google Scholar
[256]
L da Cruz, K Fynes, O Georgiadis, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol. 2018, 36(4): 328-337.
DOI Google Scholar
[257]
M Mandai, A Watanabe, Y Kurimoto, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017, 376(11): 1038-1046.
Google Scholar
[258]
GJ Chen, YL Wang, ZY Xu, et al. Neural stem cell-like cells derived from autologous bone mesenchymal stem cells for the treatment of patients with cerebral palsy. J Transl Med. 2013, 11: 21.
DOI Google Scholar
[259]
S Nafissi, H Kazemi, T Tiraihi, et al. Intraspinal delivery of bone marrow stromal cell-derived neural stem cells in patients with amyotrophic lateral sclerosis: a safety and feasibility study. J Neurol Sci. 2016, 362: 174-181.
DOI Google Scholar
[260]
GK Steinberg, D Kondziolka, LR Wechsler, et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study. Stroke. 2016, 47(7): 1817-1824.
DOI Google Scholar
[261]
GK Steinberg, D Kondziolka, LR Wechsler, et al. Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study. J Neurosurg. 2018: 1-11.
DOI Google Scholar
[262]
ZG Wang, Y Luo, L Chen, et al. Safety of neural stem cell transplantation in patients with severe traumatic brain injury. Exp Ther Med. 2017, 13(6): 3613-3618.
DOI Google Scholar
[263]
P Taupin. HuCNS-SC (StemCells). Curr Opin Mol Ther. 2006, 8(2): 156-163.
Google Scholar
[264]
NR Selden, A Al-Uzri, SL Huhn, et al. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr. 2013, 11(6): 643-652.
DOI Google Scholar
[265]
AD Levi, DO Okonkwo, P Park, et al. Emerging safety of intramedullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury. Neurosurgery. 2018, 82(4): 562-575.
DOI Google Scholar
[266]
AD Levi, KD Anderson, DO Okonkwo, et al. Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury. J Neurotrauma. 2019, 36(6): 891-902.
DOI Google Scholar
[267]
Z Luan, WP Liu, SQ Qu, et al. Effects of neural progenitor cell transplantation in children with severe cerebral palsy. Cell Transplant. 2012, 21(Suppl 1): S91-S98.
DOI Google Scholar
[268]
JC Shin, KN Kim, J Yoo, et al. Clinical trial of human fetal brain-derived neural stem/progenitor cell transplantation in patients with traumatic cervical spinal cord injury. Neural Plast. 2015, 2015: 630932.
DOI Google Scholar
[269]
E Curtis, JR Martin, B Gabel, et al. A first-in-human, phase I study of neural stem cell transplantation for chronic spinal cord injury. Cell Stem Cell. 2018, 22(6): 941-950.e6.
DOI Google Scholar
[270]
D Kalladka, J Sinden, K Pollock, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet. 2016, 388(10046): 787-796.
DOI Google Scholar
[271]
GZ Zhang, Y Li, JL Reuss, et al. Stable intracerebral transplantation of neural stem cells for the treatment of paralysis due to ischemic stroke. Stem Cells Transl Med. 2019, 8(10): 999-1007.
DOI Google Scholar
[272]
HR Martinez, MT Gonzalez-Garza, JE Moreno-Cuevas, et al. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy. 2009, 11(1): 26-34.
DOI Google Scholar
[273]
HR Martínez, JF Molina-Lopez, MT González-Garza, et al. Stem cell transplantation in amyotrophic lateral sclerosis patients: methodological approach, safety, and feasibility. Cell Transplant. 2012, 21(9): 1899-1907.
DOI Google Scholar
[274]
A Zali, L Arab, F Ashrafi, et al. Intrathecal injection of CD133-positive enriched bone marrow progenitor cells in children with cerebral palsy: feasibility and safety. Cytotherapy. 2015, 17(2): 232-241.
DOI Google Scholar
[275]
GA Moviglia, R Fernandez Viña, JA Brizuela, et al. Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy. 2006, 8(3): 202-209.
DOI Google Scholar
[276]
GA Moviglia, G Varela, JA Brizuela, et al. Case report on the clinical results of a combined cellular therapy for chronic spinal cord injured patients. Spinal Cord. 2009, 47(6): 499-503.
DOI Google Scholar
[277]
GA Moviglia, MT Moviglia-Brandolino, GS Varela, et al. Feasibility, safety, and preliminary proof of principles of autologous neural stem cell treatment combined with T-cell vaccination for ALS patients. Cell Transplant. 2012, 21(Suppl 1): S57-S63.
DOI Google Scholar
[278]
LY Qiao, FJ Huang, MS Zhao, et al. A two-year follow-up study of cotransplantation with neural stem/progenitor cells and mesenchymal stromal cells in ischemic stroke patients. Cell Transplant. 2014, 23(1_suppl): 65-72.
DOI Google Scholar
[279]
UG Thakkar, AV Vanikar, HL Trivedi. Co-infusion of autologous adipose tissue derived neuronal different- tiated mesenchymal stem cells and bone marrow derived hematopoietic stem cells, a viable therapy for post-traumatic brachial plexus injury: a case report. Biomed J. 2014, 37(4): 237-240.
DOI Google Scholar
[280]
UG Thakkar, AV Vanikar, HL Trivedi, et al. Infusion of autologous adipose tissue derived neuronal differentiated mesenchymal stem cells and hemato- poietic stem cells in post-traumatic paraplegia offers a viable therapeutic approach. Adv Biomed Res. 2016, 5: 51.
DOI Google Scholar
[281]
AS Ammar, Y Osman, AT Hendam, et al. A method for reconstruction of severely damaged spinal cord using autologous hematopoietic stem cells and platelet-rich protein as a biological scaffold. Asian J Neurosurg. 2017, 12(4): 681-690.
DOI Google Scholar
[282]
HY Huang, HS Sharma, L Chen, et al. 2018 yearbook of neurorestoratology. J Neurorestoratology. 2019, 1(1): 11-20.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Received: 10 May 2020
Revised: 25 May 2020
Accepted: 28 May 2020
Published: 04 August 2020
Issue date: June 2020

Copyright

© The authors 2020

Rights and permissions

This article is published with open access at http://jnr.tsinghuajournals.com

Return